213 related articles for article (PubMed ID: 18998128)
21. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.
Borbulevych OY; Insaidoo FK; Baxter TK; Powell DJ; Johnson LA; Restifo NP; Baker BM
J Mol Biol; 2007 Oct; 372(5):1123-36. PubMed ID: 17719062
[TBL] [Abstract][Full Text] [Related]
22. CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity.
Baumgaertner P; Schmidt J; Costa-Nunes CM; Bordry N; Guillaume P; Luescher I; Speiser DE; Rufer N; Hebeisen M
Front Immunol; 2022; 13():973986. PubMed ID: 36032094
[TBL] [Abstract][Full Text] [Related]
23. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a qualitative analysis.
Palermo B; Campanelli R; Garbelli S; Mantovani S; Robustelli Della Cuna G; Necker A; Manganoni AM; Carella G; Rivoltini L; Lantelme E; Giachino C
Melanoma Res; 2002 Oct; 12(5):491-8. PubMed ID: 12394191
[TBL] [Abstract][Full Text] [Related]
25. Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes.
Storkus WJ; Herrem C; Kawabe M; Cohen PA; Bukowski RM; Finke JH; Wesa AK
Crit Rev Immunol; 2007; 27(5):485-93. PubMed ID: 18197809
[TBL] [Abstract][Full Text] [Related]
26. A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.
Walters JN; Ferraro B; Duperret EK; Kraynyak KA; Chu J; Saint-Fleur A; Yan J; Levitsky H; Khan AS; Sardesai NY; Weiner DB
Mol Ther; 2017 Apr; 25(4):976-988. PubMed ID: 28237837
[TBL] [Abstract][Full Text] [Related]
27. Establishment of HLA-DR4 transgenic mice for the identification of CD4+ T cell epitopes of tumor-associated antigens.
Yatsuda J; Irie A; Harada K; Michibata Y; Tsukamoto H; Senju S; Tomita Y; Yuno A; Hirayama M; Abu Sayem M; Takeda N; Shibuya I; Sogo S; Fujiki F; Sugiyama H; Eto M; Nishimura Y
PLoS One; 2013; 8(12):e84908. PubMed ID: 24386437
[TBL] [Abstract][Full Text] [Related]
28. An immunogenic personal neoantigen vaccine for patients with melanoma.
Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
[TBL] [Abstract][Full Text] [Related]
29. Human leucocyte antigen class I-redirected anti-tumour CD4
Tan MP; Dolton GM; Gerry AB; Brewer JE; Bennett AD; Pumphrey NJ; Jakobsen BK; Sewell AK
Clin Exp Immunol; 2017 Jan; 187(1):124-137. PubMed ID: 27324616
[TBL] [Abstract][Full Text] [Related]
30. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex.
Slansky JE; Rattis FM; Boyd LF; Fahmy T; Jaffee EM; Schneck JP; Margulies DH; Pardoll DM
Immunity; 2000 Oct; 13(4):529-38. PubMed ID: 11070171
[TBL] [Abstract][Full Text] [Related]
31. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
[TBL] [Abstract][Full Text] [Related]
32. The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity.
Graner MW; Romanoski A; Katsanis E
Int J Hyperthermia; 2013 Aug; 29(5):380-9. PubMed ID: 23725202
[TBL] [Abstract][Full Text] [Related]
33. Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitope.
Baratin M; Kayibanda M; Ziol M; Romieu R; Briand JP; Guiller JG; Viguier M
J Pept Sci; 2002 Jul; 8(7):327-34. PubMed ID: 12148782
[
